Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PCA062 · 1 trial · 3 indications
| Arm | Type | Description |
|---|---|---|
| Triple Negative Breast Cancer | EXPERIMENTAL | - |
| Head and Neck Cancer | EXPERIMENTAL | - |
| Esophageal Cancer | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PCA062 | DRUG | - |
Inclusion criteria: 1. Male or female ≥ 18 years of age 2. Documented pCAD expressing tumor cells with the exception of HNSCC and ESCC. An archived tumor sample collected within 36 months prior to baseline if available, or a new tumor biopsy sample must be available for molecular pre-screening. 3. ...
PCA062 is an investigational small molecule being studied for the treatment of triple negative breast cancer. It is also being evaluated in head and neck cancer and esophageal cancer. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
PCA062 targets pCAD, a protein that is present in certain tumors. The drug is designed to bind to pCAD-positive cells, which are found in triple negative breast cancer, head and neck cancer, and esophageal cancer. This targeted approach is being investigated in a Phase 1 clinical trial.
PCA062 is being developed by Novartis AG, a multinational pharmaceutical company headquartered in Switzerland. Novartis trades on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical research to evaluate the safety and efficacy of PCA062 in cancer patients.
PCA062 is currently in Phase 1 clinical development. It has completed one Phase 1 trial, which was a controlled study involving 47 participants. The drug is still investigational and has not received FDA approval for any indication.
PCA062 has been studied in one clinical trial with the identifier NCT02375958, titled 'PCA062 in pCAD-positive Tumors.' This Phase 1 study enrolled 47 participants with triple negative breast cancer, head and neck cancer, or esophageal cancer. The trial was conducted in the United States, France, Italy, Japan, Singapore, and Spain.
PCA062 is a unique investigational compound developed by Novartis. It is not known to be marketed under any other name. The drug is being studied specifically for its ability to target pCAD-positive tumors, and it remains in early-stage clinical development.